The carbon footprint of pharmaceuticals for diabetes and cardiovascular diseases

Study summary

No information provided.

Study identification

• EU PAS number:
  EUPAS1000000641
• Study ID:
  1000000641
• Official title and acronym:
  The carbon footprint of pharmaceuticals for diabetes and cardiovascular diseases
• DARWIN EU® study:
  No
• Study countries:
  Denmark
• Study description:
  Objective: This scoping review aims to gather published knowledge about the carbon footprint of pharmaceuticals for diabetes (ATC A) and cardiovascular disease (ATC C, excluding C05A) reported in peer reviewed publications.; Purpose: To enhance the role health professionals, play in reducing the carbon footprint of the most prescribed pharmaceuticals globally.
• Study status:
  Ongoing

Research institutions and networks

Institutions

University of Copenhagen

Bispebjerg and Frederiksberg Hospital

Technical University of Denmark

Study timelines

Date when funding contract was signed

Planned:01/05/2025

Study start date

Planned:01/06/2025

Actual:01/06/2025

Data analysis start date

Planned:01/09/2025

Date of final study report

Planned:01/01/2026

Sources of funding

More details on funding

No funding was used

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable